Get the Stockscreener App
10.37
1.57%
0.16
Delcath Systems Inc stock is traded at $10.37, with a volume of 529.58K.
It is up +1.57% in the last 24 hours and up +3.39% over the past month.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.
See More
Previous Close:
$10.21
Open:
$10.21
24h Volume:
529.58K
Relative Volume:
0.66
Market Cap:
$359.84M
Revenue:
$2.07M
Net Income/Loss:
$-47.68M
P/E Ratio:
-3.6773
EPS:
-2.82
Net Cash Flow:
$-31.31M
1W Performance:
+0.29%
1M Performance:
+3.39%
6M Performance:
-7.82%
1Y Performance:
-24.14%
1-Day Range:
$10.08
$10.64
1-Week Range:
$10.00
$10.64
52-Week Range:
$8.12
$18.23
Delcath Systems Inc Stock (DCTH) Company Profile
Name
Delcath Systems Inc
Sector
Industry
Phone
(518) 743-8892
Address
566 QUEENSBURY AVENUE, QUEENSBURY, NY
Compare DCTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DCTH
Delcath Systems Inc
|
10.37 | 354.29M | 2.07M | -47.68M | -31.31M | -2.82 |
|
ABT
Abbott Laboratories
|
121.76 | 214.80B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
SYK
Stryker Corp
|
363.78 | 138.62B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
BSX
Boston Scientific Corp
|
88.07 | 133.46B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
MDT
Medtronic Plc
|
96.76 | 126.92B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
84.35 | 49.03B | 5.88B | 1.34B | 799.60M | 2.3489 |
Delcath Systems Inc Stock (DCTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-28-24 | Initiated | Craig Hallum | Buy |
| May-14-24 | Initiated | Stephens | Overweight |
| Jul-26-22 | Resumed | Canaccord Genuity | Buy |
| Dec-10-21 | Initiated | H.C. Wainwright | Buy |
| Mar-09-21 | Initiated | Canaccord Genuity | Buy |
| Jan-05-21 | Initiated | BTIG Research | Buy |
| Jun-01-20 | Initiated | Laidlaw | Buy |
View All
Delcath Systems Inc Stock (DCTH) Latest News
Is Delcath Systems Inc backed by strong institutional buyingLong Setup & Daily Growth Stock Investment Tips - baoquankhu1.vn
Market Catalysts: Is ODYS forming a bullish divergenceEarnings Performance Report & Real-Time Buy Signal Notifications - baoquankhu1.vn
Price-Driven Insight from (DCTH) for Rule-Based Strategy - Stock Traders Daily
Delcath Systems expects FY revenue of $85.2 million - MSN
Delcath Systems: Stabilizing Fundamentals Justify A Rating Upgrade (NASDAQ:DCTH) - Seeking Alpha
Delcath Systems Reports Strong Preliminary 2025 Results - TipRanks
NY-based Delcath Systems expects Q4 2025 revenue to hit USD 20.7M - Medical Buyer
Aug Closing: Is Delcath Systems Inc subject to activist investor interestJuly 2025 Institutional & Target Return Focused Stock Picks - baoquankhu1.vn
Delcath Systems, Inc. (NASDAQ:DCTH) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Delcath Systems, Inc. (NASDAQ:DCTH) Q2 2025 Earnings Call Transcript - MSN
EBITDA per share of Delcath Systems, Inc. – DUS:DV3R - TradingView — Track All Markets
Delcath reports $85.2 million in 2025 revenue, strong cash position By Investing.com - Investing.com Nigeria
Delcath Systems (NASDAQ:DCTH) Stock Rating Upgraded by Wall Street Zen - MarketBeat
DCTH FinancialsIncome Statement - Quiver Quantitative
DCTH: HC Wainwright Reiterates Buy Rating with $30 Price Target - GuruFocus
HC Wainwright Reaffirms Buy Rating for Delcath Systems (NASDAQ:DCTH) - MarketBeat
Delcath Systems, Inc. Provides Earnings Guidance for the Fourth Quarter and Full Year 2025 - MarketScreener
Delcath Systems (DCTH) Exceeds Revenue Expectations in Q4 and Fu - GuruFocus
Delcath Systems announces preliminary fourth quarter and full year 2025 financial results - marketscreener.com
Delcath reports $85.2 million in 2025 revenue, strong cash position - Investing.com
Delcath Systems Announces Preliminary Fourth Quarter and Full Year 2025 Financial Results - The AI Journal
Will Delcath Systems Inc. stock outperform Nasdaq indexWeekly Market Report & Fast Entry Momentum Alerts - ulpravda.ru
ETF Watch: Will Delcath Systems Inc. stock remain a Wall Street favoriteTrade Ideas & Reliable Price Breakout Signals - Улправда
How resilient is Delcath Systems Inc. stock in market downturnsJuly 2025 Retail & Weekly Top Gainers Alerts - ulpravda.ru
Will Delcath Systems Inc. stock remain a Wall Street favoriteMarket Volume Summary & Daily Technical Forecast Reports - Улправда
Shorts Report: Will Delcath Systems Inc stock remain a Wall Street favorite2025 Earnings Impact & Daily Growth Stock Investment Tips - Bộ Nội Vụ
Delcath Systems, Inc. (DCTH) Beats Q4 Earnings and Revenue Estimates - MSN
A Look At Delcath Systems (DCTH) Valuation After New Phase 3 FOCUS Subgroup Data On HEPZATO KIT - Sahm
Under the Radar: 3 Microcap Growers Passing a Tough Test - Benzinga
Will Delcath Systems Inc. stock sustain high P E ratios2026 world cup usa national team round of 16 key players high defensive line match prediction expert opinion - Улправда
Will New HEPZATO KIT Subgroup Data on Tumor Burden and Survival Change Delcath Systems' (DCTH) Narrative - Sahm
(DCTH) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
Should New HEPZATO Subgroup Data and Delcath’s Targeted Strategy Require Action From DCTH Investors? - Yahoo Finance
Are options traders betting on a big move in Delcath Systems stock? - MSN
Delcath Systems Inc Stock Analysis and ForecastLong-Term Growth Stocks & Fast Growing Investment Plans - earlytimes.in
Hepzato Kit Safe, Effective in Metastatic, Unresectable Uveal Melanoma - Cure Today
Are Options Traders Betting on a Big Move in Delcath Systems Stock? - Nasdaq
Delcath Systems publishes results from subgroup analyses of FOCUS study - Yahoo Finance
Delcath’s HEPZATO shows consistent efficacy across patient subgroups By Investing.com - Investing.com Nigeria
Delcath Systems (DCTH) Reveals Key Findings from FOCUS Study Sub - GuruFocus
Delcath’s HEPZATO shows consistent efficacy across patient subgroups - Investing.com
Which metastatic uveal melanoma patients gain most from a liver-directed drug? - Stock Titan
Simplify Asset Management Inc. Increases Stock Position in Delcath Systems, Inc. $DCTH - MarketBeat
Glenmark Pharmaceuticals Limited (532296) Gets Regulatory ApprovalFibonacci Extensions & Build Wealth With Strategy - bollywoodhelpline.com
Book value per share of Delcath Systems, Inc. – MUN:DV3R - TradingView — Track All Markets
Bearish Setup: Is Delcath Systems Inc stock a smart buy before Fed meetingTrade Entry Summary & Advanced Technical Signal Analysis - Bộ Nội Vụ
Precision Trading with Delcath Systems Inc. (DCTH) Risk Zones - Stock Traders Daily
Delcath Systems, Inc. (NASDAQ:DCTH) is a favorite amongst institutional investors who own 51% - Yahoo Finance
Delcath Systems (STU:DV3R) EV-to-OCF : 19.88 (As of Dec. 21, 2025) - GuruFocus
Why Delcath Systems Inc. (DV3R) stock stays on buy lists2025 Biggest Moves & Entry Point Strategy Guides - bolumsonucanavari.com
Delcath Systems Earnings Notes - Trefis
Delcath Systems Inc Stock (DCTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
Delcath Systems Inc Stock (DCTH) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| MICHEL GERARD J | CHIEF EXECUTIVE OFFICER |
Nov 11 '25 |
Buy |
8.53 |
11,500 |
98,049 |
330,834 |
| Vukovic Vojo | CHIEF MEDICAL OFFICER |
Jun 12 '25 |
Option Exercise |
4.78 |
42,000 |
200,760 |
168,882 |
0.42%
1.96%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):